The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis

Cancer Letters

Volumn 238, Issue 1, 2006, Pages 111-118

  Horie, Naoyuki ^a   Murata, Hiroaki ^a   Nishigaki, Yasunori ^a   Matsui, Takaaki ^a   Segawa, Hidekazu ^b   Nogawa, Masaki ^b   Yuasa, Takeshi ^b   Kimura, Shinya ^b   Maekawa, Taira ^b   Fushiki, Shinji ^a   Kubo, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; Bisphosphonates; Osteosarcoma; P glycoprotein; YM175; YM529

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; INCADRONIC ACID; MINODRONIC ACID;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; GTP-BINDING PROTEINS; IMIDAZOLES; MICE; OSTEOSARCOMA;

MURINAE;

EID: 33744925129     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.041     Document Type: Article

References (35)

1. K.K. Unni, Dahlin's BONE TUMORS General Aspects and Date on 11,0809 Cases. Fifth ed., pp. 143-183.
2. Takeshita H., Gebhardt M.C., Springfield D.S., Kusuzaki K., and Mankin H.J. Experimental models for the study of drug resistance in osteosarcoma: p-glycoprotein-positive, murine osteosarcoma cell lines. J. Bone Joint Surg. 78-A (1996) 366-375
3. Link M.P. Preoperative and adjuvant chemotherapy in osteosarcoma. In: Novak J.F., and Mcmaster J.H. (Eds). Frontiers of Osteosarcoma Research: Interdisciplinary Survey of Clinical and Research Advances (1993), Hogrefe and Huber, Seattle 41-49
4. Hirata M., Kusuzaki K., Takeshita H., Hashiguchi S., Hirasawa Y., and Ashihara T. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Anticancer Res. 21 (2001) 317-320
5. Fairchild C.R., Ivy S.P., Kao-Shan C.-S., Whang-Peng J., Rosen N., Israel M.A., et al. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res. 47 (1987) 5141-5148
6. Giavazzi R., Kartner N., and Hart I.R. Expression of cell surface P-glycoprotein by an Adriamycin-resistant murine fibrosarcoma. Cancer Chemother. Pharmacol. 13 (1984) 145-147
7. Kartner N., Riordan J.R., and Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221 (1983) 1285-1288
8. Russel R.G., and Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 (1999) 97-106
9. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., and Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 255 (1999) 491-494
10. van Beek E., Pieterman E., Cohen L., Lowwik C., and Papapoulos S. Nitrogen-containing bishosphonates inhibit isopentenyl pyrophosphate isomerase/ farnesyl pyrophosphate synthas activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun. 255 (2001) 235-242
11. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2001) 235-242
12. Benford H.L., McGowan N.W., Helfrich M.H., Nuttall M.E., and Rogers M.J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28 (2001) 465-473
13. Coxon F.P., Helfrich M.H., Van't Hof R., Sebti S., Ralston S.H., Hamilton A., et al. Protein geranylgeraylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. 15 (2000) 1467-1476
14. Iguchi T., Miyakawa Y., Yamamoto K., Kizaki M., and Ikeda Y. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 15 (2003) 719-727
15. Nishida S., Fujii Y., Yoshioka S., Kikuichi S., Tsubaki M., and Irimajiri K. A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci. 73 (2003) 2655-2664
16. Kuroda J., Kimura S., Segawa H., Kobayashi Y., Yoshikawa T., Urasaki Y., et al. The third-generation bisphosphonate zolendronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102 (2003) 2229-2235
17. Lee M.V., Fong E.M., Singer F.R., and Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61 (2001) 2602-2608
18. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action, Alendronate localization on rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88 (1991) 2095-2105
19. Evdokius A., Labrinidis A., Bouralexis S., Hay S., and Findlay D.M. Induction of cell death of human osteogenic sarcoma cells by zolendronic acid resembles anoikis. Bone 33 (2003) 216-228
20. Mackie P.S., Fishier J.L., Zhou H., and Choong P.F. Bisphosphonates regulate cell growth and gene expression in UMR 106-01 clonal rat osteosarcoma cell line. Br. J. Cancer 84 (2001) 951-958
21. Sonnemann J., Eckervogt V., Truckenbord B., Boos J., Winkelmann W., and Valen F.V. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth. Anti-Cancer Drug 12 (2001) 459-465
22. Shipman C.M., Croucher P.I., Russell R.G., Helfrich M.H., and Rogers M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58 (1998) 5294-5297
23. Michigami T., Yamato H., Suzuki H., Nagai-Itagaki Y., Sato K., and Ozono K. Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy. J. Endocrinol. 171 (2001) 249-257
24. Yoshida Y., Moriya A., Kitamura K., Inazu M., Okimoto N., Okazaki Y., and Nakamura T. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J. Bone Miner. Res. 13 (1998) 1011-1022
25. Bell R.S., Roth Y.F., Gebhardt M.C., Bell D.F., Rosenberg A.E., Mankin H.J., and Suit H.D. Timing of chemotherapy and surgery in a murine osteosarcoma model. Cancer Res. 48 (1988) 5533-5538
26. Choi C.H., Sedlacek R.S., and Suit H.D. Radiation-induced osteogenic sarcoma of C3H mouse: effects of corynebacterium parvum and WBI on its natural history and response to irradiation. Eur. J. Cancer 15 (1979) 433-442
27. Asai T., Ueda T., Itoh K., Yoshioka K., Aoki Y., Mori S., and Yoshikawa H. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int. J. Cancer 76 (1998) 418-422
28. Takeshita H., Kusuzaki K., Tsuji Y., Hirata M., Hashiguchi S., Nakamura S., et al. Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209, Anticancer Res. 18 (1998) 739-742
29. Hansen M.B., Nielsen S.E., and Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119 (1989) 203-210
30. Kimura S., Maekawa T., Hirakawa K., Murakami A., and Abe T. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 55 (1995) 1379-1384
31. Reszka A.A., Halasy-Nagy J., and Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyto model for esophageal irritation. Mol. Pharmacol. 59 (2001) 193-202
32. Turhan A.G., Solary E., Vainchenker W., and Dusanter-Fourt I. Molecular pathophysiology of chronic myelogeneous leukemia. Hematol. Cell Ther. 40 217-221 (1998) 199
33. Neri A., Knowles D.M., Greco A., McCormick F., and Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc. Natl. Acad. Sci. USA 85 (1998) 9268-9272
34. Katz M.E., and McCormick F. Signal transduction from multiple Ras effectors. Curr. Opin. Genet. Dev. 7 (1997) 75-79
35. Kuwazuru Y., Yoshimura A., Hanada S., Utsunomiya A., Makino T., Ishibashi K., Kodama M., Iwahashi M., Arima T., and Akiyama S. Expression of the multidrug transporter, p-glycoprotein, in acute leukemia cells and correction to clinical drug resistance, Cancer 66 (1990) 868-873